You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

7 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gefitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2021
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
PACLitaxel,
gemcitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2018
Guidelines and Advice
Status: Current
Version: 2
Oct 2018
Guidelines and Advice
Status: Current
May 2018
Guidelines and Advice
Status: Current
ID: ES SMG-2
Jun 2018
Guidelines and Advice
Status: Current
ID: PET 19
Version: n/a
Nov 2018
Guidelines and Advice
Status: Current
ID: N/A
Version: Final
May 2018